SCHEMBL154378

SCHEMBL154378

N#CCCCN1CCCCCC1

nearest known ligand 0.83

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.83
POLB P06746 2/20 0.60
HRH3 Q9Y5N1 10/20 0.56
ALDH1A1 P00352 1/20 0.54
PKM P14618 1/20 0.54
SMN1; SMN2 Q16637 2/20 0.45
CYP1A2 P05177 1/20 0.43
MAPK1 P28482 1/20 0.43
GAA P10253 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL150332 1.00 MAPT (0.83) MAPTPOLBHRH3ALDH1A1PKM
SCHEMBL146416 0.98 MAPT (0.86) MAPTPOLBHRH3ALDH1A1PKM
SCHEMBL151103 0.93 MAPT (0.95) MAPTPOLBHRH3ALDH1A1PKM
SCHEMBL151720 0.93 MAPT (0.95) MAPTPOLBHRH3ALDH1A1PKM
SCHEMBL27895291 0.93
SCHEMBL6738785 0.91 MAPT (0.91) MAPTPOLBHRH3ALDH1A1PKM
SCHEMBL7228795 0.91 MAPT (0.91) MAPTPOLBHRH3ALDH1A1PKM
SCHEMBL9322332 0.91 MAPT (0.91) MAPTPOLBHRH3ALDH1A1PKM
SCHEMBL149979 0.91 MAPT (1.00) MAPTPOLBHRH3ALDH1A1PKM
SCHEMBL9206204 0.88 MAPT (0.95) MAPTPOLBHRH3ALDH1A1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0210904-B1 PHENYL-(3-HEXAMETHYLENE IMINOPROPYL) KETONE, PROCESS FOR ITS PREPARATION AND THERAPEUTICAL USE LABORATOIRE L. LAFON Société anonyme dite: (FR) 1989-09-06 EP claimed
EP-0110748-B1 DERIVATIVES OF PHENYL-(3-AMINOPROPYL) KETONE, THEIR THERAPEUTICAL USE AND PROCESS FOR THEIR PREPARATION LABORATOIRE L. LAFON Société anonyme dite: (FR) 1987-04-22 EP claimed
EP-0210904-A1 Phenyl-(3-hexamethylene iminopropyl) ketone, process for its preparation and therapeutical use LABORATOIRE L. LAFON Société anonyme dite: (FR) 1987-02-04 EP claimed
EP-0110748-A1 Derivatives of phenyl-(3-aminopropyl) ketone, their therapeutical use and process for their preparation LABORATOIRE L. LAFON Société anonyme dite: (FR) 1984-06-13 EP claimed
US-9469710-B2 Polymers functionalized with nitrile compounds containing a protected amino group BRIDGESTONE CORPORATION (JP) 2016-10-18 US disclosed
CN-103333275-B With the polymkeric substance of functionalized with nitrile compounds comprising protected amino BRIDGESTONE CO., LTD. (JP) 2015-07-29 CN disclosed
US-20150148489-A1 POLYMERS FUNCTIONALIZED WITH NITRILE COMPOUNDS CONTAINING A PROTECTED AMINO GROUP BRIDGESTONE CORPORATION (JP) 2015-05-28 US disclosed
US-8735494-B2 Polymers functionalized with nitrile compounds containing a protected amino group BRIDGESTONE CORPORATION (JP) 2014-05-27 US disclosed
CN-103333275-A Polymers functionalized with nitrile compounds containing a protected amino group BRIDGESTONE CORP 2013-10-02 CN disclosed
CN-102361887-B Polymers functionalized with nitrile compounds containing a protected amino group BRIDGESTONE CORP 2013-06-26 CN disclosed
US-20130085227-A1 POLYMERS FUNCTIONALIZED WITH NITRILE COMPOUNDS CONTAINING A PROTECTED AMINO GROUP BRIDGESTONE CORPORATION (JP) 2013-04-04 US disclosed
US-8344066-B2 Polymers functionalized with nitrile compounds containing a protected amino group BRIDGESTONE CORPORATION (JP) 2013-01-01 US disclosed
US-20070190041-A1 Novel benzothiazepine and bensothiepine compounds ASHAI KASEI PHARAMA CORPORATION (JP) 2007-08-16 US disclosed
US-20040176361-A1 Fused heterocyclic compound and medicinal use thereof MITSUBISHI PHARMA CORPORATION (JP) 2004-09-09 US disclosed
EP-1396488-A1 FUSED HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2004-03-10 EP disclosed
EP-0210904-B1 PHENYL-(3-HEXAMETHYLENE IMINOPROPYL) KETONE, PROCESS FOR ITS PREPARATION AND THERAPEUTICAL USE LABORATOIRE L. LAFON Société anonyme dite: (FR) 1989-09-06 EP disclosed
US-4758560-A Phenyl-(3-hexamethyleneiminopropyl)-ketone SOCIETE ANONYME DITE: LABORATOIRE L. LAFON (FR) 1988-07-19 US disclosed
EP-0110748-B1 DERIVATIVES OF PHENYL-(3-AMINOPROPYL) KETONE, THEIR THERAPEUTICAL USE AND PROCESS FOR THEIR PREPARATION LABORATOIRE L. LAFON Société anonyme dite: (FR) 1987-04-22 EP disclosed
EP-0210904-A1 Phenyl-(3-hexamethylene iminopropyl) ketone, process for its preparation and therapeutical use LABORATOIRE L. LAFON Société anonyme dite: (FR) 1987-02-04 EP disclosed
EP-0110748-A1 Derivatives of phenyl-(3-aminopropyl) ketone, their therapeutical use and process for their preparation LABORATOIRE L. LAFON Société anonyme dite: (FR) 1984-06-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040176361-A1 Fused heterocyclic compound and medicinal use thereof PARP11, PARP1, CD38 MAPT 1241/4885POLB 784/4885HRH3 2016/4885
US-20070190041-A1 Novel benzothiazepine and bensothiepine compounds SLC10A1, GOT1, CES1 MAPT 2335/4885POLB 4164/4885HRH3 404/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.